NASDAQ:VRNA

Verona Pharma (VRNA) Stock Forecast, Price & News

$16.56

-0.01 (-0.06%)

(As of 09/25/2023 ET)

Compare

Today's Range: $16.38
▼
$16.79
50-Day Range: $16.57
▼
$22.09
52-Week Range: $8.41
▼
$26.44

Volume: 221,903 shs
Average Volume: 469,345 shs
Market Capitalization: $10.53 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.60

Verona Pharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 96.9% Upside
$32.60 Price Target
Short Interest: Bearish
0.61% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$1.46 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.86) to ($1.09) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

898th out of 961 stocks

Pharmaceutical Preparations Industry

425th out of 452 stocks

3.5

Analyst's Opinion

Consensus Rating
Verona Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.60, Verona Pharma has a forecasted upside of 96.9% from its current price of $16.56.
Amount of Analyst Coverage
Verona Pharma has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
0.61% of the outstanding shares of Verona Pharma have been sold short.
Short Interest Ratio / Days to Cover
Verona Pharma has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Verona Pharma has recently increased by 1.58%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Verona Pharma does not currently pay a dividend.
Dividend Growth
Verona Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VRNA.

1.1

News and Social Media Coverage

Search Interest
5 people have searched for VRNA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
MarketBeat Follows
4 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Verona Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,460,799.00 in company stock.
Percentage Held by Insiders
Only 3.90% of the stock of Verona Pharma is held by insiders.
Percentage Held by Institutions
Only 9.89% of the stock of Verona Pharma is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Verona Pharma are expected to decrease in the coming year, from ($0.86) to ($1.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Verona Pharma is -22.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Verona Pharma is -22.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Verona Pharma has a P/B Ratio of 5.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Verona Pharma (NASDAQ:VRNA) Stock

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

VRNA Price History

30 days | 90 days | 365 days | Advanced Chart

VRNA Stock News Headlines

September 15, 2023 | americanbankingnews.com

Wedbush Reiterates Outperform Rating for Verona Pharma (NASDAQ:VRNA)

September 11, 2023 | msn.com

Verona Pharma’s ensifentrine inches closer to approval decision in COPD

September 25, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

September 11, 2023 | markets.businessinsider.com

Verona Pharma (VRNA) Receives a Buy from H.C. Wainwright

September 11, 2023 | finance.yahoo.com

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

September 6, 2023 | finance.yahoo.com

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

August 31, 2023 | finance.yahoo.com

Christina Ackermann Joins Verona Pharma as Non-Executive Director

August 8, 2023 | seekingalpha.com

Verona Pharma: Targeting The Large COPD Market

September 25, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

August 8, 2023 | finance.yahoo.com

Verona Pharma plc (NASDAQ:VRNA) Q2 2023 Earnings Call Transcript

August 8, 2023 | finance.yahoo.com

Verona Pharma plc's (NASDAQ:VRNA) institutional investors lost 14% over the past week but have profited from longer-term gains

August 6, 2023 | markets.businessinsider.com

Truist Financial Sticks to Their Buy Rating for Verona Pharma (VRNA)

August 3, 2023 | finance.yahoo.com

Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

June 30, 2023 | fool.com

Verona Pharma Plc (NASDAQ: VRNA)

June 28, 2023 | finance.yahoo.com

Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine

June 27, 2023 | markets.businessinsider.com

Wedbush Remains a Buy on Verona Pharma (VRNA)

June 27, 2023 | markets.businessinsider.com

Truist Financial Keeps Their Buy Rating on Verona Pharma (VRNA)

June 27, 2023 | finanznachrichten.de

Verona Pharma plc: Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

June 27, 2023 | finance.yahoo.com

Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

June 16, 2023 | finance.yahoo.com

VRNA - Verona Pharma plc

June 7, 2023 | msn.com

Truist Securities Maintains Verona Pharma Plc - ADR (VRNA) Buy Recommendation

June 2, 2023 | markets.businessinsider.com

Verona Pharma (VRNA) Gets a Buy from H.C. Wainwright

May 28, 2023 | msn.com

Verona Pharma: Poised For A Breakthrough In COPD Treatment Amidst Favorable Financial Position

May 18, 2023 | seekingalpha.com

Verona Pharma: Revolutionizing COPD With First Triple Mechanism Inhaled Drug

May 16, 2023 | benzinga.com

Massive Insider Trade At Verona Pharma

May 13, 2023 | seekingalpha.com

Verona Pharma plc (VRNA) Q1 2023 Earnings Call Transcript

May 12, 2023 | msn.com

Canaccord Genuity Maintains Verona Pharma Plc - ADR (VRNA) Below Average Recommendation

See More Headlines

Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

VRNA Company Calendar

Last Earnings: 8/03/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VRNA
CUSIP: N/A
CIK: 1657312
Web: www.veronapharma.com
Phone: 011-44-0-2032834200
Fax: N/A
Employees: 35
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $32.60
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $31.00
Forecasted Upside/Downside: +96.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-68,700,000.00
Net Margins: N/A
Pretax Margin: -11,151.31%
Return on Equity: -20.30%
Return on Assets: -17.79%

Debt

Debt-to-Equity Ratio: 0.07
Current Ratio: 26.29
Quick Ratio: 26.29

Sales & Book Value

Annual Sales: $460,000.00
Price / Sales: 22,884.12
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.05 per share
Price / Book: 5.43

Miscellaneous

Outstanding Shares: 635,670,000
Free Float: 610,879,000
Market Cap: $10.53 billion
Optionable: Not Optionable
Beta: 0.21

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. David S. Zaccardelli (Age 58)
Pres, CEO & Exec. Director
Comp: $1.05M

Mr. Mark W. Hahn (Age 60)
Chief Financial Officer
Comp: $784.38k

Dr. Kathleen A. Rickard (Age 65)
Chief Medical Officer
Comp: $655k

Ms. Claire Louise Poll L.C.S.W. (Age 56)
B.A., B Juris, LLB, ASIA, Gen. Counsel

Ms. Victoria Stewart
Director of Communications

Mr. Matthew Casbon
VP of Sales, Marketing & Training

Ms. Ostra Jewell
Sr. VP of HR

Dr. Peter Spargo (Age 61)
Sr. VP of Chemistry Manufacturing & Controls

Dr. Tara Rheault M.P.H. (Age 46)
Ph.D., Sr. VP of R&D

Mr. Christopher Martin
Sr. VP of Commercial

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VRNA Stock - Frequently Asked Questions

Should I buy or sell Verona Pharma stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRNA shares.
View VRNA analyst ratings or view top-rated stocks.
What is Verona Pharma's stock price forecast for 2023?: 5 equities research analysts have issued 12 month price targets for Verona Pharma's shares. Their VRNA share price forecasts range from $31.00 to $35.00. On average, they expect the company's stock price to reach $32.60 in the next year. This suggests a possible upside of 96.9% from the stock's current price.
View analysts price targets for VRNA or view top-rated stocks among Wall Street analysts.
How have VRNA shares performed in 2023?: Verona Pharma's stock was trading at $26.13 at the beginning of the year. Since then, VRNA stock has decreased by 36.6% and is now trading at $16.56.
View the best growth stocks for 2023 here.
When is Verona Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our VRNA earnings forecast.
How were Verona Pharma's earnings last quarter?: Verona Pharma plc (NASDAQ:VRNA) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.16.
What ETF holds Verona Pharma's stock ?: ALPS Medical Breakthroughs ETF holds 60,171 shares of VRNA stock, representing 1.19% of its portfolio.

What other stocks do shareholders of Verona Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).
When did Verona Pharma IPO?: (VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.
What is Verona Pharma's stock symbol?: Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."
Who are Verona Pharma's major shareholders?: Verona Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Jennison Associates LLC (0.22%), Nicholas Investment Partners LP (0.18%), Bellevue Group AG (0.09%), Woodline Partners LP (0.08%), Affinity Asset Advisors LLC (0.07%) and BlackRock Inc. (0.06%). Insiders that own company stock include Anders Ullman, Claire Poll, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Mark W Hahn, Orbimed Advisors Llc and Patrick John Finn.
View institutional ownership trends.
How do I buy shares of Verona Pharma?: Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Verona Pharma's stock price today?: One share of VRNA stock can currently be purchased for approximately $16.56.
How much money does Verona Pharma make?: Verona Pharma (NASDAQ:VRNA) has a market capitalization of $10.53 billion and generates $460,000.00 in revenue each year. The company earns $-68,700,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.
How can I contact Verona Pharma?: Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The official website for the company is www.veronapharma.com. The company can be reached via phone at 011-44-0-2032834200 or via email at verona@argotpartners.com.

This page (NASDAQ:VRNA) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial